Efficacy of Azithromycin Injection Combined with Levofloxacin Capsule and Ambroxol Injection in the Treatment of Mycoplasma Pneumonia

Authors

  • Ruizhen Meng Department of Pharmacy, Luohe Central Hospital, 462300 Luohe, Henan, China Author
  • Zuomin Wu Department of Pharmacy, Luohe Central Hospital, 462300 Luohe, Henan, China Author
  • Qi Song Department of Pharmacy, Luohe Central Hospital, 462300 Luohe, Henan, China Author
  • Rui Wang Department of Pharmacy, Luohe Central Hospital, 462300 Luohe, Henan, China Author

DOI:

https://doi.org/10.62767/jecacm502.3080

Keywords:

azithromycin, levofloxacin, ambroxol, mycoplasma pneumonia

Abstract

Objective: To investigate the clinical efficacy and safety of combining azithromycin injection with levofloxacin capsule and ambroxol injection for the treatment of Mycoplasma pneumonia. Methods: A total of 160 cases of patients with mycoplasma pneumonia were randomly assigned to either the control group or the experimental group, with 80 cases in each group. In the control group, azithromycin injection was administered at a dosage of 10 mg/kg once daily via intravenous drip. The experimental group received treatment based on the control group regimen, supplemented with levofloxacin capsules at a dosage of 0.2 g (2 capsules) twice daily and ambroxol injection at a dosage of 1.2-1.6 mg/(kg.d), given 2-3 times per day through slow intravenous injection lasting for 2-3 minutes. Both groups underwent a treatment duration of 7 days. Clinical efficacy, antipyretic time, cough extinction time, lung rales extinction time, and adverse drug reactions were compared between the two groups. Results: The test group exhibited an effective treatment rate of 88% for mycoplasma pneumonia, whereas the control group was 74%. The test group demonstrated significantly shorter durations for fever, cough, and lung rale disappearance compared to the control group. Conclusion: The combination of azithromycin, levofloxacin, and ambroxol significantly enhances the efficacy in treating mycoplasma pneumonia. It can further shorten improvement signs and has high safety. It is worth application for non-pediatric patients with mycoplasma infection.

References

Saraya T. The History of Mycoplasma pneumoniae Pneumonia. Frontiers in Microbiology 2016; 7: 364.

Saliba E, Sayad A, Alameddine L, et al. Mycoplasma pneumonia and atypical acute hemorrhagic edema of infancy. American Journal of Emergency Medicine 2021; 41: 266.e3-266.e5.

Young YS, Jeong JH, Ae YE, et al. Effects of Methylprednisolone Pulse Therapy on Refractory Mycoplasma pneumoniae Pneumonia in Children. Allergy Asthma & Immunology Research 2014; 6(1): 22-26.

Xu X, Wu L, Sheng Y, et al. Airway microbiota in children with bronchial mucus plugs caused by Mycoplasma pneumoniae pneumonia. Respiratory Medicine 2020; 170: 105902.

Zhao H, Li S, Cao L, et al. Surveillance of Mycoplasma pneumoniae infection among children in Beijing from 2007 to 2012. Chinese Medical Journal 2014; 127(7): 1244-1248.

Miyashita N, Narita M, Tanaka T, et al. Histological findings in severe Mycoplasma pneumoniae pneumonia. Journal of Medical Microbiology 2017; 66(5): 690-692.

Chilet F, Iqbal AM, Mitzov N, et al. Acute saddle pulmonary embolism: A rare complication of mycoplasma pneumonia. Respiratory Medicine Case Reports 2020; 30: 101033.

Meka SG, Mohr M, Nair GB, et al. Autoimmune pulmonary alveolar proteinosis mimicking Mycoplasma pneumonia in an adolescent. Respiratory Medicine Case Reports 2020; 30: 101100.

Parrott GL, Takeshi K, Jiro F. A Compendium for Mycoplasma pneumoniae. Frontiers in Microbiology 2016; 7: 1-16.

Zhao F, Guan X, Li J, et al. Real-Time PCR and Quantitative Culture for Mycoplasma pneumoniae Load in Pharyngeal Swabs from Children at Preliminary Diagnosis and Discharge. BioMed Research International 2020; 2020: 9814916.

Qu J, Gu L, Wu J, et al. Accuracy of IgM antibody testing, FQ-PCR and culture in laboratory diagnosis of acute infection by Mycoplasma pneumoniae in adults and adolescents with community-acquired pneumonia. BMC Infectious Diseases 2013; 13: 1-6.

Han R,Yu Q,Zhang G, et al. Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children. Pakistan Journal of Medical Sciences 2020; 36(2): 156-159.

Wang F, Nan K, Hao L, et al. Effects of a combination of erythromycin sequential therapy and azithromycin on lung function and inflammatory factors in children with severe mycoplasma pneumonia. Pakistan Journal of Pharmaceutical Sciences 2021; 34(6(Special)): 2447-2454.

Wang J, Yang C. Clinical effect of sequential therapy with azithromycin in children mycoplasma pneumoniae pneumonia. Pakistan Journal of Pharmaceutical Sciences 2018; 31(4(Special)): 1649-1652.

Yu Y, Chen C. Clinical observation of aerosol inhalation of azithromycin combined with budesonide suspension in the treatment of mycoplasma pneumoniae pneumonia in children. Panminerva Medica 2021.

Peng Y, Chen Z, Li Y, et al. Combined therapy of Xiaoer Feire Kechuan oral liquid and azithromycin for mycoplasma Pneumoniae pneumonia in children: A systematic review & meta-analysis. Phytomedicine 2022; 96: 153899.

Qiu Y, Xu J, Yang Y, et al. Effect of azithromycin combined with ambroxol hydrochloride on immune response to mycoplasma pneumoniae pneumonia in children. Minerva Pediatrics 2022; 74(5): 626-628.

Ha SG, Oh KJ, Ko KP, et al. Therapeutic Efficacy and Safety of Prolonged Macrolide, Corticosteroid, Doxycycline, and Levofloxacin against Macrolide-Unresponsive Mycoplasma pneumoniae Pneumonia in Children. Journal of Korean Medical Science 2018; 33(43): e268.

Parrott GL, Kinjo T, Fujita J. A Compendium for Mycoplasma pneumoniae. Frontiers in Microbiology 2016; 7: 513.

Lee Y, Chang C, Lee W, et al. Altered chemokine profile in Refractory Mycoplasma pneumoniae pneumonia infected children. Journal of Microbiology, Immunology and Infection 2021; 54(4): 673-679.

Chen Z, Shi Q, Peng Y, et al. Traditional Chinese Medicine Oral Liquids Combined With Azithromycin for Mycoplasma pneumoniae Pneumonia in Children: A Bayesian Network Meta-Analysis. Frontiers in Pharmacology 2021; 12: 652412.

Zhang H, Sun C, Yu Z. Effect of azithromycin sequential therapy combined with budesonide nebulization on chest CT changes in children with mycoplasma pneumonia. Minerva Gastroenterology 2023; 69(3): 447-449.

Yin M. Effect of Qingfei Huatan Huoxue Decoction combined with azithromycin on pulmonary function and inflammatory factors in children with Mycoplasma pneumonia. Pakistan Journal of Pharmaceutical Sciences 2021; 34(6(Supplementary)): 2317-2323.

Derbie A, Mekonnen D, Woldeamanuel Y, et al. Azithromycin resistant gonococci: a literature review. Antimicrobial Resistance & Infection Control 2020; 9(1): 138.

Smith C, Egunsola O, Choonara I, et al. Use and safety of azithromycin in neonates: a systematic review. BMJ Open 2015; 5(12): e008194.

Zhang GM, Huang ZY, Sun R, et al. Xiao'er Xiaoji Zhike Oral Liquid Combined with Azithromycin for Mycoplasma pneumoniae Pneumonia in Children: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine 2020; 2020: 9740841.

Shan LS, Liu X, Kang XY, et al. Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children. World Journal of Pediatrics 2017; 13(4): 321-327.

Samsa GP, Matchar DB, Harnett J, et al. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial. Chest Journal 2005; 128(5): 3246-3254.

Published

2024-04-30

Data Availability Statement

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Issue

Section

Original Research

Most read articles by the same author(s)

<< < 4 5 6 7 8 9